RBC Capital Markets analyst Randall Stanicky reiterates Outperform rating and $42 price target on Teva Pharmaceuticals Industries (NYSE: TEVA), suggesting strategic questions remain, despite the company reporting 2016 fourth quarter results above consensus.

Stanicky comments, "TEVA reported 4Q above Street expectations and reaffirmed 2017 guidance with some further color around the year. The bull case in TEVA lacks conviction and change is needed. We look to CEO search/ strategic review, potential for break-up, and potential upside from generic Copaxone surprise as opportunity but near-term confidence remains low. No change to PT but EPS moves lower to reflect greater competitive pressures."

For an analyst ratings summary and ratings history on Teva Pharma click here. For more ratings news on Teva Pharma click here.

Shares of Teva Pharma closed at $34.00 yesterday.